Reading MCK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MCK free→Reading MCK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MCK free→QuarterlyIQ Insights · MCK
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On June 9, 2026, certain of McKesson Corporation’s (the “Company”) subsidiaries, including McKesson Medical-Surgical Top Holdings, Inc. (the “Borrower”), entered into an amendment (the “Amendment”) to the Credit Agreement , dated as of April 1, 2026, among, the Borrower, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent (as so amended, the “Credit Agreement”), to provide for a $2,…
Results of Operations and Financial Condition. On May 7, 2026, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter and fiscal year ended on March 31, 2026 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of…
Entry into a Material Definitive Agreement. On April 24, 2026, McKesson Corporation (“McKesson” or the “Company”) entered into a Credit Agreement (the “New Revolving Credit Facility”) among the Company, as borrower, the lenders party thereto, Bank of America, N.A., as administrative agent, and the other parties thereto. The New Revolving Credit Facility replaces the Company’s existing $1.0 billion 364-day senior unsecured revolving credit facility, dated as of May 8, 2025 (the “Existing 364-D…
I tem 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information in
Entry into a Material Definitive Agreement. On April 1, 2026, certain of McKesson Corporation’s (the “Company”) subsidiaries, including McKesson Medical-Surgical Top Holdings, Inc. (the “Borrower”), entered into a credit agreement (the “Credit Agreement”) with the lenders and issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent providing for (i) a $750.0 million senior secured term “A” loan facility due 2031 (the “Term Loan A-1 Facility”), (i…
Departure of Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Retirement of Principal Financial Officer On March 3, 2026, Britt J. Vitalone, the company’s Executive Vice President and Chief Financial Officer, gave notice of his intention to retire from that role. Mr. Vitalone’s last day as our CFO will be May 28, 2026, and he will remain an employee through July 1, 2026. Mr. Vitalone thereafter will serve as a non-employee advisor to the company…
Results of Operations and Financial Condition. On February 4, 2026, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on December 31, 2025 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, a…
Results of Operations and Financial Condition. On November 5, 2025, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on September 30, 2025 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934,…
Results of Operations and Financial Condition. The information set forth in
Results of Operations and Financial Condition. On August 6, 2025, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on June 30, 2025 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amen…
Regulation FD Disclosure. Today, June 9, 2025, McKesson Corporation's (McKesson) executives are scheduled to meet with various investors and analysts. During these meetings, they will discuss McKesson’s growth strategies, operational performance, business and market trends and financial outlook. Today, McKesson is providing the following updates to its Fiscal Year 2026 Financial Outlook. McKesson is increasing its full year Adjusted Earnings per Diluted Share guide from a range of $36.75 to $…
Creation of a Direct Financial Obligation The information set forth in
Other Events. Closing of Notes Offering On May 20, 2025, McKesson Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell $650,000,000 aggregate principal amount of its 4.650% Notes due 2030 (the “ 2030 Notes”), $650,000,000 aggregate principal amount of its 4.950% Notes due 2032 (the “2032 Notes”) and $700,000,000 aggregate princip…
Results of Operations and Financial Condition. On May 8, 2025, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter and fiscal year ended on March 31, 2025 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of…
Results of Operations and Financial Condition. On February 5, 2025, McKesson reported the Company’s preliminary results for the quarter ended on December 31, 2024 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act…
Results of Operations and Financial Condition. On February 5, 2025, McKesson Corporation (“Company”) reported the Company’s preliminary results for the quarter ended on December 31, 2024 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as am…
Results of Operations and Financial Condition. On November 6, 2024, McKesson Corporation (“Company”) reported the Company’s preliminary results for the quarter ended on September 30, 2024 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as a…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Other Events. Closing of Notes Offering On September 5, 2024, McKesson Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell $500,000,000 aggregate principal amount of its 4.250% Notes due 2029 (the “Notes”). On September 10, 2024, the Notes were issued pursuant to the Indenture, dated February 15, 2023 (the “Indenture”), between…
Regulation FD Disclosure. McKesson Corporation participated in the Wells Fargo 2024 Healthcare Conference on September 5, 2024, as previously noticed in the company’s August 7, 2024 earnings release and on its investor relations website investor.mckesson.com. During the conference webcast, McKesson affirmed fiscal 2025 full year Adjusted Earnings per Diluted Share guidance in the range of $31.75 to $32.55. McKesson also indicated it anticipates second quarter fiscal 2025 Adjusted earnings per…
Results of Operations and Financial Condition. On August 7, 2024, McKesson Corporation (“Company”) reported the Company’s preliminary results for the quarter ended on June 30, 2024 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…
Departure of Directors; Election of Director On May 31, 2024, the Board of Directors (“Board”) of McKesson Corporation (“Corporation”) elected Deborah Dunsire, M.D. as a director of the Corporation and appointed her to the Board’s Compensation and Talent Committee and Finance Committee, effective June 3, 2024. Dr. Dunsire joins the Board with over 30 years of experience leading organizations in the biopharmaceutical, oncology and other specialty industries. Most recently, from 2018 to 2023, s…
Results of Operations and Financial Condition. On May 7, 2024, McKesson Corporation (“Company”) reported the Company’s preliminary results for the quarter and fiscal year ended on March 31, 2024 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 193…
Results of Operations and Financial Condition. On February 7, 2024, McKesson Corporation (“Company”) reported the Company’s preliminary results for the quarter ended on December 31, 2023 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as am…
Election of Directors. On January 8, 2024, the Board of Directors (“Board”) of McKesson Corporation (“Corporation”) elected Kevin Ozan as a director of the Corporation and appointed him to the Board’s Audit Committee and Finance Committee, effective January 8, 2024. Mr. Ozan retired from McDonald’s Corporation, a leading global food service retailer, in June 2023 after 25 years of service. He most recently served as senior executive vice president, strategic initiatives from September 2022 to…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.